Address
Email address
Phone number
Website
https://tbdpharmatech.com/TBD Pharmatech – Contract Development and ManufacturingTBD Pharmatech specialises in Active Pharmaceutical Ingredients, advanced intermediates, and the development and production of fine chemicals
Name
osaühing TBD Pharmatech
Registry code
11204964
VAT number
EE101057350
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
10.02.2006 (18)
Financial year
01.01-31.12
Capital
7 136.00 €
Activity
46711 - Wholesale of solid fuels 21101 - Manufacture of basic pharmaceutical products
4 115 740 €
-179 441 €
-4%
2 386 €
(estimate is approximate)
4 879 620 €
58
Submitted
No tax arrears
-4%
-3%
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| KemInvent OÜ 12771636 | 70% - 4 995.00 EUR | - | - | |
| Andrus Tasa 10.01.1966 (58) | - | Board member | Indirect ownership | |
| Tõnis Tasa 30.10.1989 (35) | - | Board member | - | |
| Olga Tšubrik 25.11.1979 (44) | - | - | Indirect ownership | |
| aktsiaselts Biotehnoloogia Park Kinnisvara 10834232 | - | - | - | Founder |
| Ago Rinken 13.06.1960 (64) | - | - | - | Founder |
| Allan Nurk 16.02.1961 (63) | - | - | - | Founder |
| Margus Pooga 07.08.1957 (67) | - | - | - | Founder |
| Uno Mäeorg 22.08.1950 (74) | - | - | - | Founder |
| Ursel Soomets 18.07.1962 (62) | - | - | - | Founder |
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Celvia CC AS 11673707 | - | - | - | Founder |
| 2019 20.05.2020 | 2020 24.05.2021 | 2021 24.05.2022 | 2022 27.06.2023 | 2023 25.06.2024 | |
|---|---|---|---|---|---|
| Total Revenue | 3 255 697 € | 4 568 917 € | 4 841 495 € | 5 168 441 € | 4 115 740 € |
| Net profit (loss) for the period | 946 069 € | 1 469 997 € | 1 292 402 € | 234 758 € | -179 441 € |
| Profit Margin | 29% | 32% | 27% | 5% | -4% |
| Current Assets | 1 517 804 € | 2 660 699 € | 3 387 676 € | 4 436 335 € | 3 869 498 € |
| Fixed Assets | 919 322 € | 1 234 477 € | 1 963 862 € | 1 529 432 € | 1 657 623 € |
| Total Assets | 2 437 126 € | 3 895 176 € | 5 351 538 € | 5 965 767 € | 5 527 121 € |
| Current Liabilities | 375 786 € | 363 839 € | 527 799 € | 907 270 € | 647 501 € |
| Non Current Liabilities | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - |
| Share Capital | - | - | - | - | - |
| Equity | 2 061 340 € | 3 531 337 € | 4 823 739 € | 5 058 497 € | 4 879 620 € |
| Employees | 35 | 44 | 48 | 60 | 58 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 1 685 144.16 € | 225 221.26 € | 236 776.97 € | 63 |
| 2023 Q4 | 971 856.71 € | 201 862.88 € | 213 991.02 € | 60 |
| 2023 Q3 | 699 168.68 € | 227 222.28 € | 239 670.3 € | 60 |
| 2023 Q2 | 1 614 405.79 € | 186 006.49 € | 199 986.44 € | 61 |
| 2023 Q1 | 1 166 585.21 € | 202 565.31 € | 216 919.14 € | 64 |
| 2022 Q4 | 1 622 264.28 € | 174 586.86 € | 187 465.18 € | 70 |
| 2022 Q3 | 1 558 499.38 € | 180 642.65 € | 194 184.7 € | 65 |
| 2022 Q2 | 803 903.73 € | 160 191.15 € | 171 975.68 € | 61 |
| 2022 Q1 | 1 696 525.74 € | 160 988.43 € | 172 621.89 € | 57 |
| 2021 Q4 | 1 434 646.04 € | 126 205.42 € | 133 696.27 € | 60 |
| 2021 Q3 | 1 378 461.41 € | 147 704.27 € | 158 985.11 € | 55 |
| 2021 Q2 | 1 421 441.74 € | 132 915.2 € | 142 967.5 € | 59 |
| 2021 Q1 | 1 074 740.78 € | 134 266.22 € | 144 253.75 € | 55 |
| 2020 Q4 | 1 217 763.87 € | 122 068.65 € | 130 788.06 € | 50 |
| 2020 Q3 | 1 151 313.51 € | 117 678.63 € | 126 209.44 € | 47 |
| 2020 Q2 | 1 934 858.61 € | 106 476.75 € | 114 368.62 € | 42 |
| 2020 Q1 | 850 156.14 € | 107 868.18 € | 115 850.46 € | 40 |
